Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Initiation of LGD-6972 Phase 2 in T2D

September 13, 2016 12:29 PM EDT
Get Alerts LGND Hot Sheet
Price: $105.62 --0%

Rating Summary:
    8 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade LGND Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy with a price target of $151 after the company announced the initiation of a Phase 2 clinical trial with the Company’s glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM).

Analyst Joseph Pantginis commented today:

This study initiation is an important event for LGND, in our belief. It represents a new category of potential value drivers for the company. Since the company now has the financial resources, in can selectively move assets through a further stage of development. This should result in added de-risking of the program which could yield higher economic value to the company when/if outlicensed. At ADA 2015, LGND presented impressive data (in our belief) from a Phase Ib multiple ascending dose (MAD) data for LGD-6972. The detailed data are shown below, but this was a randomized, double-blind, placebocontrolled study where both healthy volunteers and type 2 diabetic patients saw increasing doses of the drug with a 14-day dosing period. Three doses were tested, 5, 10 and 15 mg and pharmacokinetic data support once per day dosing. 14-day data show a safe and well tolerated profile and importantly, no SAEs or treatment discontinuation. From an efficacy standpoint, '6972 lowered fasting plasma glucose throughout the 14-day period in a dose dependent fashion.

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital

Add Your Comment